-
1
-
-
0029909112
-
Normalization of insulin response to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
-
Rachman J., Gribble F.M., Barrow B.A., Levy J.C., Buchanan K.D., and Turner R.C. Normalization of insulin response to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45 (1996) 1524-1530
-
(1996)
Diabetes
, vol.45
, pp. 1524-1530
-
-
Rachman, J.1
Gribble, F.M.2
Barrow, B.A.3
Levy, J.C.4
Buchanan, K.D.5
Turner, R.C.6
-
2
-
-
0027248866
-
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
-
Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
-
(1993)
Diabetologia
, vol.36
, pp. 741-744
-
-
Nauck, M.A.1
Kleine, N.2
Orskov, C.3
Holst, J.J.4
Willms, B.5
Creutzfeldt, W.6
-
3
-
-
0030068620
-
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
-
Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
-
(1996)
J Clin Endocrinol Metab
, vol.81
, pp. 327-332
-
-
Willms, B.1
Werner, J.2
Holst, J.J.3
Orskov, C.4
Creutzfeldt, W.5
Nauck, M.A.6
-
4
-
-
0032976939
-
Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
-
Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
-
(1999)
Diabetes Care
, vol.22
, pp. 1137-1143
-
-
Toft-Nielsen, M.B.1
Madsbad, S.2
Holst, J.J.3
-
5
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type-2 Diabetes: a parallel-group study
-
Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type-2 Diabetes: a parallel-group study. Lancet 359 (2002) 824-830
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
Holst, J.J.4
-
6
-
-
0033513455
-
Exendin-4 stimulates both beta-cell replication and neogenesis resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
-
Xu G., Stoffers D.A., Habener J.F., and Bonneir-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
-
(1999)
Diabetes
, vol.48
, pp. 2270-2276
-
-
Xu, G.1
Stoffers, D.A.2
Habener, J.F.3
Bonneir-Weir, S.4
-
7
-
-
0035405821
-
GLP-1 and exendin-4 stimulate beta-cell mass neogenesis in STZ-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
-
Tourrel C., Balbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. GLP-1 and exendin-4 stimulate beta-cell mass neogenesis in STZ-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (2001) 1562-1570
-
(2001)
Diabetes
, vol.50
, pp. 1562-1570
-
-
Tourrel, C.1
Balbe, D.2
Lacorne, M.3
Meile, M.J.4
Kergoat, M.5
Portha, B.6
-
8
-
-
0036828227
-
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
-
Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
-
(2002)
Endocrinology
, vol.143
, pp. 4397-4408
-
-
Farilla, L.1
Hui, H.2
Bertolotto, C.3
Kang, E.4
Bulotta, A.5
Di Mario, U.6
Perfetti, R.7
-
9
-
-
33748331194
-
Chronic inhibition of DPPIV with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes
-
Mu J., Woods J., Zhou Y.-P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., et al. Chronic inhibition of DPPIV with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
-
(2006)
Diabetes
, vol.55
, pp. 1695-1704
-
-
Mu, J.1
Woods, J.2
Zhou, Y.-P.3
Roy, R.S.4
Li, Z.5
Zycband, E.6
Feng, Y.7
Zhu, L.8
Li, C.9
Howard, A.D.10
-
10
-
-
3242730474
-
Role of incretin hormones in the regulation of insulin secretion in diabetic and non diabetic humans
-
Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and non diabetic humans. Am J Physiol Endocrinol Metab 287 (2004) E199-E206
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
-
-
Holst, J.J.1
Gromada, J.2
-
11
-
-
0028799007
-
Differential processing of proglucagon by the subtilisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide
-
Rouille Y., Martin S., and Steiner D.F. Differential processing of proglucagon by the subtilisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270 (1995) 26488-26496
-
(1995)
J Biol Chem
, vol.270
, pp. 26488-26496
-
-
Rouille, Y.1
Martin, S.2
Steiner, D.F.3
-
12
-
-
0027227370
-
Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post prandial and 24h secretion patterns
-
Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., and Marks V. Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post prandial and 24h secretion patterns. J Endocrinol 138 (1993) 159-166
-
(1993)
J Endocrinol
, vol.138
, pp. 159-166
-
-
Elliott, R.M.1
Morgan, L.M.2
Tredger, J.A.3
Deacon, S.4
Wright, J.5
Marks, V.6
-
14
-
-
24044470321
-
Physiology and patho physiology of glucagon-like peptide-1: the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress
-
Bojanowska E. Physiology and patho physiology of glucagon-like peptide-1: the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity and stress. Med Sci Monit 11 (2005) RA271-RA278
-
(2005)
Med Sci Monit
, vol.11
-
-
Bojanowska, E.1
-
15
-
-
33645071360
-
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
-
Demonstrates that both L and K cells are present in equal numbers in human duodenum and that both express glucokinase and glucose transporters. The early rise in GLP-1 plasma levels after an oral glucose tolerance test can be caused by the presence of L cells in human duodenum.
-
Theodorakis M.J., Carlson O., Michopoulos S., Doyle M.E., Juhaszovz M., Petraki K., and Egan J.M. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290 (2006) 550-559. Demonstrates that both L and K cells are present in equal numbers in human duodenum and that both express glucokinase and glucose transporters. The early rise in GLP-1 plasma levels after an oral glucose tolerance test can be caused by the presence of L cells in human duodenum.
-
(2006)
Am J Physiol Endocrinol Metab
, vol.290
, pp. 550-559
-
-
Theodorakis, M.J.1
Carlson, O.2
Michopoulos, S.3
Doyle, M.E.4
Juhaszovz, M.5
Petraki, K.6
Egan, J.M.7
-
16
-
-
24944577486
-
Alpha cell function in health and disease: influence of glucagons-like peptide-1
-
Dunning B.E., Foley J.E., and Ahren B. Alpha cell function in health and disease: influence of glucagons-like peptide-1. Diabetologia 48 (2005) 1700-1713
-
(2005)
Diabetologia
, vol.48
, pp. 1700-1713
-
-
Dunning, B.E.1
Foley, J.E.2
Ahren, B.3
-
17
-
-
15044354562
-
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
-
Larsen P.J., and Holst J.J. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128 (2005) 97-107
-
(2005)
Regul Pept
, vol.128
, pp. 97-107
-
-
Larsen, P.J.1
Holst, J.J.2
-
18
-
-
0141532690
-
A novel glucose sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line
-
Gribble F.M., Williams L., Simpson A.K., and Reimann F. A novel glucose sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52 (2003) 1147-1154
-
(2003)
Diabetes
, vol.52
, pp. 1147-1154
-
-
Gribble, F.M.1
Williams, L.2
Simpson, A.K.3
Reimann, F.4
-
19
-
-
0034623757
-
Glucose-dependent insulin release from genetically engineered K cells
-
Cheung A.T., Dayanandan B., Lewis J.T., Korbutt G.S., Rajotte R.V., Bryer-Ash M., Boyla M.O., Wolfe M.M., and Kieffer T.J. Glucose-dependent insulin release from genetically engineered K cells. Science 290 (2000) 1959-1962
-
(2000)
Science
, vol.290
, pp. 1959-1962
-
-
Cheung, A.T.1
Dayanandan, B.2
Lewis, J.T.3
Korbutt, G.S.4
Rajotte, R.V.5
Bryer-Ash, M.6
Boyla, M.O.7
Wolfe, M.M.8
Kieffer, T.J.9
-
20
-
-
22744442874
-
Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors
-
Clear summary of the history of DPPIV enzymes and a review of the development of DPPIV inhibitors as potential antidiabetics.
-
Demuth H.-U., McIntosch C.H.S., and Pederson R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751 (2005) 33-45. Clear summary of the history of DPPIV enzymes and a review of the development of DPPIV inhibitors as potential antidiabetics.
-
(2005)
Biochim Biophys Acta
, vol.1751
, pp. 33-45
-
-
Demuth, H.-U.1
McIntosch, C.H.S.2
Pederson, R.A.3
-
21
-
-
24944436267
-
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon like peptide-1 in the anaesthetised pig
-
Plamboeck A., Holst J.J., Carr R.D., and Deacon D.F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon like peptide-1 in the anaesthetised pig. Diabetologia 48 (2005) 1882-1890
-
(2005)
Diabetologia
, vol.48
, pp. 1882-1890
-
-
Plamboeck, A.1
Holst, J.J.2
Carr, R.D.3
Deacon, D.F.4
-
22
-
-
0033696456
-
Portal GLP-1 administration in rats augments the insulin response to glucose by neuronal mechanisms
-
Balkan B., and Li X. Portal GLP-1 administration in rats augments the insulin response to glucose by neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1449-R1454
-
(2000)
Am J Physiol Regul Integr Comp Physiol
, vol.279
-
-
Balkan, B.1
Li, X.2
-
23
-
-
0035434115
-
Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor
-
Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
-
(2001)
Diabetes
, vol.50
, pp. 1720-1728
-
-
Burcelin, R.1
Da Costa, A.2
Drucker, D.3
Thorens, B.4
-
24
-
-
27444441940
-
Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors
-
Dardevet D., Moore M.C., DiCostanzo C.A., Farmer B., Neal D.W., Snead W., Lautz M., and Cherrington A.D. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 289 (2005) G806-G814
-
(2005)
Am J Physiol Gastrointest Liver Physiol
, vol.289
-
-
Dardevet, D.1
Moore, M.C.2
DiCostanzo, C.A.3
Farmer, B.4
Neal, D.W.5
Snead, W.6
Lautz, M.7
Cherrington, A.D.8
-
25
-
-
17844399596
-
Glucagon-like peptide-1 mediates the therapeutic actions of DPPIV inhibitors
-
The authors have listed five arguments in support of GLP-1 mediating the therapeutic actions of DPPIV inhibitors.
-
Holst J.J., and Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPPIV inhibitors. Diabetologia 48 (2005) 612-615. The authors have listed five arguments in support of GLP-1 mediating the therapeutic actions of DPPIV inhibitors.
-
(2005)
Diabetologia
, vol.48
, pp. 612-615
-
-
Holst, J.J.1
Deacon, C.F.2
-
26
-
-
20044379258
-
Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones
-
Ionut V., Hucking K., Liberty I.F., and Bergmann R.N. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48 (2005) 967-975
-
(2005)
Diabetologia
, vol.48
, pp. 967-975
-
-
Ionut, V.1
Hucking, K.2
Liberty, I.F.3
Bergmann, R.N.4
-
27
-
-
0942287326
-
Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice
-
Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286 (2004) R269-R272
-
(2004)
Am J Physiol Regul Integr Comp Physiol
, vol.286
-
-
Ahren, B.1
-
28
-
-
0344357096
-
Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
-
Drucker D.J., Philippe J., Mojsov S., Chick W.L., and Habener J.F. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84 (1987) 3434-3438
-
(1987)
Proc Natl Acad Sci USA
, vol.84
, pp. 3434-3438
-
-
Drucker, D.J.1
Philippe, J.2
Mojsov, S.3
Chick, W.L.4
Habener, J.F.5
-
29
-
-
33646046535
-
Incretins and islet function
-
Ahren B. Incretins and islet function. Cur Mol Med 13 (2006) 154-161
-
(2006)
Cur Mol Med
, vol.13
, pp. 154-161
-
-
Ahren, B.1
-
30
-
-
32944473560
-
Therapeutic approaches to preserve islet mass in type 2 diabetes
-
Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57 (2006) 267-281
-
(2006)
Annu Rev Med
, vol.57
, pp. 267-281
-
-
Baggio, L.L.1
Drucker, D.J.2
-
31
-
-
33748331194
-
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes
-
Woods M.J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
-
(2006)
Diabetes
, vol.55
, pp. 1695-1704
-
-
Woods, M.J.1
Zhou, Y.P.2
Roy, R.S.3
Li, Z.4
Zycband, E.5
Feng, Y.6
Zhu, L.7
Li, C.8
Howard, A.D.9
Moller, D.E.10
-
32
-
-
2942568445
-
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
-
Buteau J., El-Assaad W., Rhodes C.J., Rosenberg L., Joly E., and Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47 (2004) 806-815
-
(2004)
Diabetologia
, vol.47
, pp. 806-815
-
-
Buteau, J.1
El-Assaad, W.2
Rhodes, C.J.3
Rosenberg, L.4
Joly, E.5
Prentki, M.6
-
33
-
-
7644243354
-
Exendin-4 dose dependently stimulates somatostatin and insulin secretion in perfused rat pancreas
-
Egido E.M., Silvestre S.A., Hernandez R., and Marco J. Exendin-4 dose dependently stimulates somatostatin and insulin secretion in perfused rat pancreas. Horm Metab Res 36 (2004) 595-600
-
(2004)
Horm Metab Res
, vol.36
, pp. 595-600
-
-
Egido, E.M.1
Silvestre, S.A.2
Hernandez, R.3
Marco, J.4
-
34
-
-
20044374696
-
β-cell-secretory products activate α-cell ATP dependent potassium channels to inhibit glucagons release
-
Franklin I., Gromada J., Gjinovci A., Theander S., and Wollheim C.B. β-cell-secretory products activate α-cell ATP dependent potassium channels to inhibit glucagons release. Diabetes 54 (2005) 1808-1815
-
(2005)
Diabetes
, vol.54
, pp. 1808-1815
-
-
Franklin, I.1
Gromada, J.2
Gjinovci, A.3
Theander, S.4
Wollheim, C.B.5
-
35
-
-
0141461415
-
Glucagon like peptide-1 receptor is involved in learning and neuroprotection
-
During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., Drucker D.J., and Haile C.N. Glucagon like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9 (2003) 1173-1179
-
(2003)
Nat Med
, vol.9
, pp. 1173-1179
-
-
During, M.J.1
Cao, L.2
Zuzga, D.S.3
Francis, J.S.4
Fitzsimons, H.L.5
Jiao, X.6
Bland, R.J.7
Klugmann, M.8
Banks, W.A.9
Drucker, D.J.10
Haile, C.N.11
-
36
-
-
22144491473
-
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in alzheimer's disease
-
This review compares the biochemical cascades activated by GLP-1 receptor in the pancreas and the brain, as well as the functions of GLP-1 (apoptosis versus cell survival).
-
Perry T., and Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in alzheimer's disease. Curr Alzheimer Res 2 (2005) 377-385. This review compares the biochemical cascades activated by GLP-1 receptor in the pancreas and the brain, as well as the functions of GLP-1 (apoptosis versus cell survival).
-
(2005)
Curr Alzheimer Res
, vol.2
, pp. 377-385
-
-
Perry, T.1
Greig, N.H.2
-
37
-
-
0036721026
-
Protection and reversal of exocitotoxic neuronal damage by glucagon like peptide-1 and exendin-4
-
Perry T., Haughey N.J., Mattson M.P., Egan J.M., and Greig N.H. Protection and reversal of exocitotoxic neuronal damage by glucagon like peptide-1 and exendin-4. J Pharmacol Exp Ther 302 (2002) 881-888
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 881-888
-
-
Perry, T.1
Haughey, N.J.2
Mattson, M.P.3
Egan, J.M.4
Greig, N.H.5
-
38
-
-
0038202937
-
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
-
Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., and Roman R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21 (2003) 1125-1135
-
(2003)
J Hypertens
, vol.21
, pp. 1125-1135
-
-
Yu, M.1
Moreno, C.2
Hoagland, K.M.3
Dahly, A.4
Ditter, K.5
Mistry, M.6
Roman, R.J.7
-
39
-
-
8544258807
-
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
-
Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., and Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287 (2004) E1209-E1215
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
-
-
Nystrom, T.1
Gutniak, M.K.2
Zhang, Q.3
Zhang, F.4
Holst, J.J.5
Ahren, B.6
Sjoholm, A.7
-
40
-
-
4344605042
-
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
-
Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., and Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
-
(2004)
Circulation
, vol.110
, pp. 955-961
-
-
Nikolaidis, L.A.1
Elahi, D.2
Hentosz, T.3
Doverspike, A.4
Huerbin, R.5
Zourelias, L.6
Stolarski, C.7
Shen, Y.T.8
Shannon, R.P.9
-
41
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., and Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005) 146-151
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
Brand, C.L.4
Yellon, D.M.5
-
42
-
-
0035046251
-
Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic b-cells by a cyclic AMP/PKA dependent mechanism
-
Wang X., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic b-cells by a cyclic AMP/PKA dependent mechanism. Endocrinology 142 (2001) 1820-1827
-
(2001)
Endocrinology
, vol.142
, pp. 1820-1827
-
-
Wang, X.1
Zhou, J.2
Doyle, M.E.3
Egan, J.M.4
-
43
-
-
33745315716
-
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass
-
Buteau J., Spatz M.L., and Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 55 (2006) 1190-1196
-
(2006)
Diabetes
, vol.55
, pp. 1190-1196
-
-
Buteau, J.1
Spatz, M.L.2
Accili, D.3
-
44
-
-
0038339191
-
cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
-
Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., and Reed J. cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev 17 (2003) 1575-1580
-
(2003)
Genes Dev
, vol.17
, pp. 1575-1580
-
-
Jhala, U.S.1
Canettieri, G.2
Screaton, R.A.3
Kulkarni, R.N.4
Krajewski, S.5
Reed, J.6
-
45
-
-
0037386156
-
Glucagon like peptide-1inhibits apoptosis of insulin-secreting cells via a cyclic 5′AMP dependent protein kinase A- and a PI3K-dependent pathway
-
Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon like peptide-1inhibits apoptosis of insulin-secreting cells via a cyclic 5′AMP dependent protein kinase A- and a PI3K-dependent pathway. Endocrinology 144 (2003) 1444-1445
-
(2003)
Endocrinology
, vol.144
, pp. 1444-1445
-
-
Hui, H.1
Nourparvar, A.2
Zhao, X.3
Perfetti, R.4
-
46
-
-
0037221488
-
Glucagon-like peptide-1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor
-
Buteau J., Foisy S., Joly E., and Prentki M. Glucagon-like peptide-1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003) 124-132
-
(2003)
Diabetes
, vol.52
, pp. 124-132
-
-
Buteau, J.1
Foisy, S.2
Joly, E.3
Prentki, M.4
-
47
-
-
2542479899
-
Minireview: glucagon like peptide-1 regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system
-
Brubaker P.L., and Drucker D.J. Minireview: glucagon like peptide-1 regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocinology 145 (2004) 2653-2659
-
(2004)
Endocinology
, vol.145
, pp. 2653-2659
-
-
Brubaker, P.L.1
Drucker, D.J.2
-
48
-
-
33745315716
-
Transcription factor FoxO1 mediates glucagon like peptide-1 effects on β-cell mass
-
Buteau J., Spatz M.L., and Accili D. Transcription factor FoxO1 mediates glucagon like peptide-1 effects on β-cell mass. Diabetes 55 (2006) 1190-1196
-
(2006)
Diabetes
, vol.55
, pp. 1190-1196
-
-
Buteau, J.1
Spatz, M.L.2
Accili, D.3
-
49
-
-
17144374877
-
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes
-
Sinclair E.M., and Drucker D.J. Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabet 12 (2005) 146-151
-
(2005)
Curr Opin Endocrinol Diabet
, vol.12
, pp. 146-151
-
-
Sinclair, E.M.1
Drucker, D.J.2
-
50
-
-
31844443202
-
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
-
Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologi 49 (2006) 253-260
-
(2006)
Diabetologi
, vol.49
, pp. 253-260
-
-
Holst, J.J.1
-
51
-
-
21744433419
-
Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes
-
Gautier J.F., Fetita S., Sobngwi E., and Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31 (2005) 233-242
-
(2005)
Diabetes Metab
, vol.31
, pp. 233-242
-
-
Gautier, J.F.1
Fetita, S.2
Sobngwi, E.3
Salaun-Martin, C.4
-
52
-
-
11144236233
-
Incretin mimetics as emerging treatment for type 2 diabetes
-
Recent review on the clinical Phase I/II trial data for exenatide and liraglutide.
-
Joy S.V., Rodgers P.T., and Scates A. Incretin mimetics as emerging treatment for type 2 diabetes. Ann Pharmacother 39 (2005) 110-118. Recent review on the clinical Phase I/II trial data for exenatide and liraglutide.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 110-118
-
-
Joy, S.V.1
Rodgers, P.T.2
Scates, A.3
-
53
-
-
0037787851
-
Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV
-
Lambeir A.M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40 (2003) 209-294
-
(2003)
Crit Rev Clin Lab Sci
, vol.40
, pp. 209-294
-
-
Lambeir, A.M.1
Durinx, C.2
Scharpe, S.3
De Meester, I.4
-
54
-
-
0033579444
-
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts
-
Park J.E., Lenter M.C., Zimmermann R.N., Garin-Chesa P., Old L.J., and Rettig W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274 (1999) 36505-36512
-
(1999)
J Biol Chem
, vol.274
, pp. 36505-36512
-
-
Park, J.E.1
Lenter, M.C.2
Zimmermann, R.N.3
Garin-Chesa, P.4
Old, L.J.5
Rettig, W.J.6
-
55
-
-
20444421293
-
Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy
-
This review summarizes the evidence that FAPα and DPPIV are potential targets for cancer therapy.
-
Kelly T. Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 8 (2005) 51-58. This review summarizes the evidence that FAPα and DPPIV are potential targets for cancer therapy.
-
(2005)
Drug Resist Updat
, vol.8
, pp. 51-58
-
-
Kelly, T.1
-
56
-
-
33646923405
-
Dipeptidyl peptidase II and leukocyte cell death
-
Maes M.B., Martinet W., Schrijvers D.M., Van der Veken P., De Meyer G.R.Y., Augustyns K., Lambeir A.-M., Scharpé S., and De Meester I. Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 72 (2006) 70-79
-
(2006)
Biochem Pharmacol
, vol.72
, pp. 70-79
-
-
Maes, M.B.1
Martinet, W.2
Schrijvers, D.M.3
Van der Veken, P.4
De Meyer, G.R.Y.5
Augustyns, K.6
Lambeir, A.-M.7
Scharpé, S.8
De Meester, I.9
-
57
-
-
25844459084
-
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes
-
Lankas G.R., Leiting B., Sinha Roy R., Eirmann G.J., Beconi M.G., Bitfu T., Chan C.-C., Edmondson S., Feeney W.P., and Thornberry N.A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Diabetes 54 (2005) 2988-2994
-
(2005)
Diabetes
, vol.54
, pp. 2988-2994
-
-
Lankas, G.R.1
Leiting, B.2
Sinha Roy, R.3
Eirmann, G.J.4
Beconi, M.G.5
Bitfu, T.6
Chan, C.-C.7
Edmondson, S.8
Feeney, W.P.9
Thornberry, N.A.10
-
58
-
-
17844407465
-
The therapeutic actions of DPPIV inhibition are not mediated by glucagon-like peptide-1
-
Nauck M.A., and El-Ouaghlidi A. The therapeutic actions of DPPIV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 (2005) 608-611
-
(2005)
Diabetologia
, vol.48
, pp. 608-611
-
-
Nauck, M.A.1
El-Ouaghlidi, A.2
-
59
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
-
Blonde L., Kleine E.J., Han J., Zhang B., Mac S.M., Poon T.H., Taylor K.L., Trautmann M.E., Kim D.D., and Kendall D.M. Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8 (2006) 436-447
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 436-447
-
-
Blonde, L.1
Kleine, E.J.2
Han, J.3
Zhang, B.4
Mac, S.M.5
Poon, T.H.6
Taylor, K.L.7
Trautmann, M.E.8
Kim, D.D.9
Kendall, D.M.10
-
60
-
-
2342599057
-
One week's treatment with the long-acting glucagon-like derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes
-
Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., Rungby J., Landau B.R., and Schmitz O. One week's treatment with the long-acting glucagon-like derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53 (2004) 1187-1194
-
(2004)
Diabetes
, vol.53
, pp. 1187-1194
-
-
Degn, K.B.1
Juhl, C.B.2
Sturis, J.3
Jakobsen, G.4
Brock, B.5
Chandramouli, V.6
Rungby, J.7
Landau, B.R.8
Schmitz, O.9
-
61
-
-
5344228270
-
The CREB coactivator TORC2 functions as a calcium- and camp-sensitive coincidence detector
-
Screaton R.A., Conkright M.D., Katoh Y., Best J.L., Canettieri G., Jeffries S., Guzman E., Niessen S., Yates III J.R., and Monminy M. The CREB coactivator TORC2 functions as a calcium- and camp-sensitive coincidence detector. Cell 48 (2004) 61-74
-
(2004)
Cell
, vol.48
, pp. 61-74
-
-
Screaton, R.A.1
Conkright, M.D.2
Katoh, Y.3
Best, J.L.4
Canettieri, G.5
Jeffries, S.6
Guzman, E.7
Niessen, S.8
Yates III, J.R.9
Monminy, M.10
|